Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus versus cyclophosphamide for pediatric crescentic Henoch-Schonlein purpura nephritis
ChiCTR2000039686Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Dec 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus, cyclophosphamide and prednisone in IgA vasculitis nephritis (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Percentage decrease in 24-hour urinary protein after 3 months of treatment. Started Dec 2020; status: recruiting.
02
Drugs
tacrolimuscyclophosphamideprednisone
03
Conditions
IgA vasculitis nephritis
Beyond the preview
Go deeper on ChiCTR2000039686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039686.